Chemotherapy Induced Peripheral Neuropathy – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Chemotherapy Induced Peripheral Neuropathy – Drugs In Development, 2023’, provides an overview of the Chemotherapy Induced Peripheral Neuropathy pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Peripheral Neuropathy
- The report reviews pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Chemotherapy Induced Peripheral Neuropathy therapeutics and enlists all their major and minor projects
- The report assesses Chemotherapy Induced Peripheral Neuropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Peripheral Neuropathy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Peripheral Neuropathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Abalone Bio IncAchelios Therapeutics Inc
Algenis
AlgoTherapeutix SAS
Amniotics AB
Annji Pharmaceutical Co Ltd
Apexian Pharmaceuticals Inc
Aphios Corp
Artelo Biosciences Inc
Asahi Kasei Pharma Corp
Augustine Therapeutics
Avantyx Pharmaceuticals LLC
AxoProtego Therapeutics LLC
Beijing 3E-Regenacy Pharmaceuticals Co Ltd
Bexion Pharmaceuticals Inc
Bright Minds Biosciences Inc
Bristol-Myers Squibb Co
CAMP Therapeutics Inc
Candel Therapeutics Inc
Daiichi Sankyo Co Ltd
EA Pharma Co Ltd
Eikonizo Therapeutics Inc
Eli Lilly and Co
Exodos Life Sciences Limited Partnership
Eydis Bio Inc
Grunenthal GmbH
Hallym University
Helsinn Healthcare SA
Hoba Therapeutics ApS
Immunophage Biotech Co Ltd
Institute of Biotechnology and Pharmaceutical Research
Jiangsu Hengrui Medicine Co Ltd
LTT Bio-Pharma Co Ltd
MAKScientific LLC
MediciNova Inc
Medifron DBT Co Ltd
Mundipharma International Ltd
Navega Therapeutics Inc
NeurExo Sciences LLC
Neuropathix Inc
NeuroTherpia Inc
Novaremed AG
Nura Bio Inc
OliPass Corporation
Ono Pharmaceutical Co Ltd
Osmol Therapeutics Inc
PharmatrophiX Inc
Regenacy Pharmaceuticals LLC
Regulonix LLC
Rudacure Co Ltd
Senzer Ltd
Serpin Pharma LLC
SiteOne Therapeutics Inc
Solasia Pharma KK
Sonnet BioTherapeutics Holdings Inc
Sova Pharmaceuticals Inc
Synerkine Pharma BV
Trevena Inc
University of Strasbourg
WEX Pharmaceuticals Inc
Winsantor Inc